Knowledge graph · Trial
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
COMPLETED
- Identifier
- CI-TRIAL-00041307
- Entity page
- /trial/NCT03357471 ↗
- Edges
- 0
- Neighbours
- none
- Drawn
- 0 of 0 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Data not yet available
No knowledge edge or registry link touches this trial on this environment. Edges appear once a source (CIViC, ChEMBL, openFDA, ClinicalTrials.gov, GDC) states one — CancerIndex does not infer them.
What CancerIndex knows
- Open Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
- Lung Non-Small Cell Carcinoma
- Malignant Colorectal Neoplasm
- ABL1
- EGFR